Rhythm Pharma's obesity drug fails to meet main goal in late-stage trial
Reuters03-17 04:05
Rhythm Pharma's obesity drug fails to meet main goal in late-stage trial
March 16 (Reuters) - Rhythm Pharmaceuticals RYTM.O said on Monday its experimental obesity drug in patients with rare genetic conditions did not meet the main goal of a late-stage trial.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Alan Barona)
((Kamal.Choudhury@thomsonreuters.com;))
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments